# Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

> **NCT04502966** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 199 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis
- Grass Pollen Allergy

## Interventions

- **BIOLOGICAL:** Dupixent®
- **BIOLOGICAL:** Grazax®
- **DRUG:** Dupixent® Placebo
- **DRUG:** Grazax® Placebo

## Key facts

- **NCT ID:** NCT04502966
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-05
- **Primary completion:** 2025-02-20
- **Final completion:** 2025-02-20
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502966, "Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04502966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*